MLTX
$14.91
-$0.08(-0.57%)
43
Overall
60
Value
20
Tech
50
Quality
Market Cap
$672.08M
Volume
875.01K
52W Range
-- - --
Target Price
$14.89
Company Overview
| Mkt Cap | $672.08M | Price | $14.91 |
| Volume | 875.01K | Change | -0.57% |
| P/E Ratio | -- | Open | $15.08 |
| Revenue | -- | Prev Close | $15.00 |
| Net Income | -- | 52W Range | -- - -- |
| Div Yield | N/A | Target | $14.89 |
| Overall | 43 | Value | 60 |
| Quality | 50 | Technical | 20 |
No chart data available
About MLTX
MoonLake Immunotherapeutics, a clinical stage biopharmaceutical company, engages in developing therapies. The company develops Sonelokimab, a novel tri-specific investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Latest News
MoonLake Immunotherapeutics Reports Q3 2025 Financial Results
TipRanks Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MLTX | $14.91 | -0.6% | 875.01K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |